COMMUNIQUÉS West-GlobeNewswire
-
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
28/07/2026 -
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
28/07/2026 -
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
28/07/2026 -
Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
28/07/2026 -
Cato Healthcare Supply Strengthens Executive Leadership Team
28/07/2026 -
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
28/07/2026 -
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
28/07/2026 -
Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy
28/07/2026 -
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
28/07/2026 -
Enlivex Announces $400,000,000 Private Placement
28/07/2026 -
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
28/07/2026 -
CorVascular Named Exclusive U.S. Importer and Vascular Distributor for ASUS FDA-Cleared Ultrasound Portfolio
28/07/2026 -
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
28/07/2026 -
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026 -
New Survey: Digestive Side Effects Cause 41% of GLP-1 Users to Suffer in Silence, Self-Adjust, or Consider Quitting
28/07/2026 -
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
28/07/2026 -
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
28/07/2026 -
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
28/07/2026 -
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
28/07/2026
Pages